Published in Psychopharmacology (Berl) on October 03, 2006
A randomized controlled pilot trial of oral N-acetylcysteine in children with autism. Biol Psychiatry (2012) 1.58
Pediatric Traumatic Brain Injury and Autism: Elucidating Shared Mechanisms. Behav Neurol (2016) 1.40
GRIN2A mutation and early-onset epileptic encephalopathy: personalized therapy with memantine. Ann Clin Transl Neurol (2014) 1.29
Ionotropic GABA and Glutamate Receptor Mutations and Human Neurologic Diseases. Mol Pharmacol (2015) 1.16
Developing drugs for core social and communication impairment in autism. Child Adolesc Psychiatr Clin N Am (2008) 1.10
Open-label memantine in fragile X syndrome. J Autism Dev Disord (2009) 1.04
Autism spectrum disorder causes, mechanisms, and treatments: focus on neuronal synapses. Front Mol Neurosci (2013) 1.04
Glutamate receptor dysfunction and drug targets across models of autism spectrum disorders. Pharmacol Biochem Behav (2011) 1.01
On the promise of pharmacotherapies targeted at cognitive and neurodegenerative components of Down syndrome. Dev Neurosci (2011) 0.99
Translational Mouse Models of Autism: Advancing Toward Pharmacological Therapeutics. Curr Top Behav Neurosci (2016) 0.97
TARGETED TREATMENTS IN AUTISM AND FRAGILE X SYNDROME. Res Autism Spectr Disord (2012) 0.94
Treatment of inattention, overactivity, and impulsiveness in autism spectrum disorders. Child Adolesc Psychiatr Clin N Am (2008) 0.94
Memantine protects rats treated with intrathecal methotrexate from developing spatial memory deficits. Clin Cancer Res (2013) 0.91
Early intervention combined with targeted treatment promotes cognitive and behavioral improvements in young children with fragile x syndrome. Case Rep Genet (2012) 0.88
Pharmacologic treatments for the behavioral symptoms associated with autism spectrum disorders across the lifespan. Dialogues Clin Neurosci (2012) 0.86
GRIN2D Recurrent De Novo Dominant Mutation Causes a Severe Epileptic Encephalopathy Treatable with NMDA Receptor Channel Blockers. Am J Hum Genet (2016) 0.85
Pharmacotherapy for the core symptoms in autistic disorder: current status of the research. Drugs (2013) 0.85
Medical treatment overview: traditional and novel psycho-pharmacological and complementary and alternative medications. Curr Opin Pediatr (2011) 0.85
The role of glutamate and its receptors in autism and the use of glutamate receptor antagonists in treatment. J Neural Transm (Vienna) (2014) 0.85
Memantine: a review of possible uses in child and adolescent psychiatry. J Can Acad Child Adolesc Psychiatry (2013) 0.84
Safety and Efficacy of Memantine in Children with Autism: Randomized, Placebo-Controlled Study and Open-Label Extension. J Child Adolesc Psychopharmacol (2016) 0.83
An open-label naturalistic pilot study of acamprosate in youth with autistic disorder. J Child Adolesc Psychopharmacol (2011) 0.82
The use of medications approved for Alzheimer's disease in autism spectrum disorder: a systematic review. Front Pediatr (2014) 0.81
Assessment and treatment in autism spectrum disorders: a focus on genetics and psychiatry. Autism Res Treat (2012) 0.79
Glutamatergic candidate genes in autism spectrum disorder: an overview. J Neural Transm (Vienna) (2014) 0.78
Advanced pharmacotherapy evidenced by pathogenesis of autism spectrum disorder. Clin Psychopharmacol Neurosci (2014) 0.78
Emerging drugs for the treatment of symptoms associated with autism spectrum disorders. Expert Opin Emerg Drugs (2010) 0.77
Memantine-induced speech problems in two patients with autistic disorder. Daru (2013) 0.76
Beta-lactam antibiotics as a possible novel therapy for managing epilepsy and autism, a case report and review of literature. Iran J Child Neurol (2015) 0.76
Common EIF4E variants modulate risk for autism spectrum disorders in the high-functioning range. J Neural Transm (Vienna) (2014) 0.76
New Therapeutic Options for Autism Spectrum Disorder: Experimental Evidences. Exp Neurobiol (2015) 0.76
Glutamatergic medication in the treatment of obsessive compulsive disorder (OCD) and autism spectrum disorder (ASD) - study protocol for a randomised controlled trial. Trials (2016) 0.75
d-Cycloserine enhances durability of social skills training in autism spectrum disorder. Mol Autism (2017) 0.75
Phenotyping, Etiological Factors, and Biomarkers: Toward Precision Medicine in Autism Spectrum Disorders. J Dev Behav Pediatr (2016) 0.75
Developing Medications Targeting Glutamatergic Dysfunction in Autism: Progress to Date. CNS Drugs (2015) 0.75
Lithium protects hippocampal progenitors, cognitive performance and hypothalamus-pituitary function after irradiation to the juvenile rat brain. Oncotarget (2017) 0.75
Effects of propranolol on conversational reciprocity in autism spectrum disorder: a pilot, double-blind, single-dose psychopharmacological challenge study. Psychopharmacology (Berl) (2016) 0.75
Autism Diagnostic Interview-Revised: a revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders. J Autism Dev Disord (1994) 42.80
Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med (2003) 6.79
Pervasive developmental disorders in preschool children: confirmation of high prevalence. Am J Psychiatry (2005) 5.52
Pervasive developmental disorders in preschool children. JAMA (2001) 5.13
The aberrant behavior checklist: a behavior rating scale for the assessment of treatment effects. Am J Ment Defic (1985) 4.59
Glutamic acid decarboxylase 65 and 67 kDa proteins are reduced in autistic parietal and cerebellar cortices. Biol Psychiatry (2002) 2.52
Linkage and association of the glutamate receptor 6 gene with autism. Mol Psychiatry (2002) 2.51
A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia. Arch Gen Psychiatry (1999) 2.44
Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist--a review of preclinical data. Neuropharmacology (1999) 2.32
Glycine and N-methyl-D-aspartate receptors: physiological significance and possible therapeutic applications. Pharmacol Rev (1998) 2.28
Excitatory amino acid receptors and synaptic plasticity. Trends Pharmacol Sci (1990) 1.90
A pilot study of D-cycloserine in subjects with autistic disorder. Am J Psychiatry (2004) 1.40
Patch clamp studies on the kinetics and selectivity of N-methyl-D-aspartate receptor antagonism by memantine (1-amino-3,5-dimethyladamantan). Neuropharmacology (1993) 1.31
Plasma amino acid levels in children with autism and their families. J Autism Dev Disord (2003) 1.24
Hypothesis: is infantile autism a hypoglutamatergic disorder? Relevance of glutamate - serotonin interactions for pharmacotherapy. J Neural Transm (Vienna) (1998) 1.21
Double-blind, placebo-controlled study of amantadine hydrochloride in the treatment of children with autistic disorder. J Am Acad Child Adolesc Psychiatry (2001) 1.19
Amantadine and memantine are NMDA receptor antagonists with neuroprotective properties. J Neural Transm Suppl (1994) 1.11
Development of amino acid receptors in frontal cortex from girls with Rett syndrome. Ann Neurol (1999) 1.01
Serotonin and amino acid content in platelets of autistic children. Acta Psychiatr Scand (1993) 1.01
Family-based association study between autism and glutamate receptor 6 gene in Chinese Han trios. Am J Med Genet B Neuropsychiatr Genet (2004) 1.01
Memantine for disruptive behavior in autistic disorder. J Clin Psychiatry (2006) 0.87
Neurochemical alterations in Rett syndrome. Brain Res Dev Brain Res (1993) 0.84
Memantine: update on the current evidence. Int J Geriatr Psychiatry (2003) 0.77
Functional impact of global rare copy number variation in autism spectrum disorders. Nature (2010) 14.66
Autism genome-wide copy number variation reveals ubiquitin and neuronal genes. Nature (2009) 9.47
Risperidone in children with autism and serious behavioral problems. N Engl J Med (2002) 9.35
A genome-wide scan for common alleles affecting risk for autism. Hum Mol Genet (2010) 3.42
Risperidone for the core symptom domains of autism: results from the study by the autism network of the research units on pediatric psychopharmacology. Am J Psychiatry (2005) 2.94
Task-shifting of antiretroviral delivery from health care workers to persons living with HIV/AIDS: clinical outcomes of a community-based program in Kenya. J Acquir Immune Defic Syndr (2010) 2.84
Individual common variants exert weak effects on the risk for autism spectrum disorderspi. Hum Mol Genet (2012) 2.46
Parent-rated anxiety symptoms in children with pervasive developmental disorders: frequency and association with core autism symptoms and cognitive functioning. J Abnorm Child Psychol (2007) 1.98
Risperidone and adaptive behavior in children with autism. J Am Acad Child Adolesc Psychiatry (2006) 1.71
Validity of the autism diagnostic interview-revised. Am J Ment Retard (2006) 1.66
Children's Yale-Brown Obsessive Compulsive Scale modified for pervasive developmental disorders. J Am Acad Child Adolesc Psychiatry (2006) 1.61
Increased prevalence of familial autoimmunity in probands with pervasive developmental disorders. Pediatrics (2003) 1.56
Medication and parent training in children with pervasive developmental disorders and serious behavior problems: results from a randomized clinical trial. J Am Acad Child Adolesc Psychiatry (2009) 1.55
Case series: use of ziprasidone for maladaptive symptoms in youths with autism. J Am Acad Child Adolesc Psychiatry (2002) 1.53
Onset and exacerbation of obsessive-compulsive disorder in pregnancy and the postpartum period. J Clin Psychiatry (2010) 1.47
Gastrointestinal symptoms in a sample of children with pervasive developmental disorders. J Autism Dev Disord (2008) 1.46
A novel approach of homozygous haplotype sharing identifies candidate genes in autism spectrum disorder. Hum Genet (2011) 1.43
Cerebrospinal fluid corticotropin-releasing factor and perceived early-life stress in depressed patients and healthy control subjects. Neuropsychopharmacology (2004) 1.41
A pilot study of D-cycloserine in subjects with autistic disorder. Am J Psychiatry (2004) 1.40
Autism: the micro-movement perspective. Front Integr Neurosci (2013) 1.32
Weight gain associated with atypical antipsychotic use in children and adolescents: prevalence, clinical relevance, and management. Paediatr Drugs (2004) 1.26
Acute and long-term safety and tolerability of risperidone in children with autism. J Child Adolesc Psychopharmacol (2005) 1.24
Neurochemistry in the pathophysiology of autism. J Clin Psychiatry (2005) 1.23
Structural and functional magnetic resonance imaging of autism spectrum disorders. Brain Res (2010) 1.22
A naturalistic retrospective analysis of psychostimulants in pervasive developmental disorders. J Child Adolesc Psychopharmacol (2004) 1.20
Atypical antipsychotics in the treatment of children and adolescents with pervasive developmental disorders. Psychopharmacology (Berl) (2013) 1.19
Atypical antipsychotics in children and adolescents with autistic and other pervasive developmental disorders. J Clin Psychiatry (2008) 1.19
Effects of short- and long-term risperidone treatment on prolactin levels in children with autism. Biol Psychiatry (2006) 1.18
High nitric oxide production in autistic disorder: a possible role for interferon-gamma. Biol Psychiatry (2004) 1.18
Weight and leptin changes among risperidone-treated youths with autism: 6-month prospective data. Am J Psychiatry (2004) 1.16
Moderators, mediators, and other predictors of risperidone response in children with autistic disorder and irritability. J Child Adolesc Psychopharmacol (2010) 1.15
Guanfacine treatment of hyperactivity and inattention in pervasive developmental disorders: a retrospective analysis of 80 cases. J Child Adolesc Psychopharmacol (2004) 1.15
Pharmacotherapy to control behavioral symptoms in children with autism. Expert Opin Pharmacother (2012) 1.12
Developing drugs for core social and communication impairment in autism. Child Adolesc Psychiatr Clin N Am (2008) 1.10
Aripiprazole for maladaptive behavior in pervasive developmental disorders. J Child Adolesc Psychopharmacol (2004) 1.09
Synergistic action of 5-HT2A antagonists and selective serotonin reuptake inhibitors in neuropsychiatric disorders. Neuropsychopharmacology (2002) 1.08
High blood monocyte counts and neopterin levels in children with autistic disorder. Am J Psychiatry (2003) 1.07
Maternal folic acid supplementation and risk of autism. JAMA (2013) 1.07
Pharmacologic treatment of autism and related disorders. Pediatr Ann (2007) 1.07
Aripiprazole in pervasive developmental disorder not otherwise specified and Asperger's disorder: a 14-week, prospective, open-label study. J Child Adolesc Psychopharmacol (2009) 1.06
Antipsychotics in the treatment of autism. J Clin Invest (2008) 1.06
The amygdala and related structures in the pathophysiology of autism. Pharmacol Biochem Behav (2002) 1.05
Effects of risperidone and parent training on adaptive functioning in children with pervasive developmental disorders and serious behavioral problems. J Am Acad Child Adolesc Psychiatry (2011) 1.05
Open-label memantine in fragile X syndrome. J Autism Dev Disord (2009) 1.04
The use of selective serotonin reuptake inhibitors in autism and related disorders. J Child Adolesc Psychopharmacol (2006) 1.04
Pharmacologic treatment of behavioral symptoms associated with autism and other pervasive developmental disorders. Curr Treat Options Neurol (2010) 1.02
Exploring the manifestations of anxiety in children with autism spectrum disorders. J Autism Dev Disord (2013) 1.02
Open-label atomoxetine for attention-deficit/ hyperactivity disorder symptoms associated with high-functioning pervasive developmental disorders. J Child Adolesc Psychopharmacol (2006) 1.02
Positive effects of methylphenidate on inattention and hyperactivity in pervasive developmental disorders: an analysis of secondary measures. Biol Psychiatry (2007) 1.00
Gastrointestinal factors in autistic disorder: a critical review. J Autism Dev Disord (2005) 1.00
Serotoninergic mechanisms in the treatment of obsessive-compulsive disorder. Drug Discov Today (2008) 1.00
Brief report: autistic disorder in three children with cytomegalovirus infection. J Autism Dev Disord (2004) 0.99
Brief report: acamprosate in fragile X syndrome. J Autism Dev Disord (2010) 0.99
Body mass index change in autism spectrum disorders: comparison of treatment with risperidone and aripiprazole. J Child Adolesc Psychopharmacol (2014) 0.99
Brief Report: social disability in autism spectrum disorder: results from Research Units on Pediatric Psychopharmacology (RUPP) Autism Network trials. J Autism Dev Disord (2013) 0.98
Multidisciplinary assessment and treatment of self-injurious behavior in autism spectrum disorder and intellectual disability: integration of psychological and biological theory and approach. J Autism Dev Disord (2015) 0.97
Trial design challenges when combining medication and parent training in children with pervasive developmental disorders. J Autism Dev Disord (2008) 0.96
Changes in the diagnostic criteria for autism in DSM-5: controversies and concerns. J Clin Psychiatry (2013) 0.95
Examination of aggression and self-injury in children with autism spectrum disorders and serious behavioral problems. Child Adolesc Psychiatr Clin N Am (2014) 0.94
A prospective open trial of guanfacine in children with pervasive developmental disorders. J Child Adolesc Psychopharmacol (2006) 0.94
Positive effects of methylphenidate on social communication and self-regulation in children with pervasive developmental disorders and hyperactivity. J Autism Dev Disord (2008) 0.94
Aripiprazole in autism spectrum disorders and fragile X syndrome. Neurotherapeutics (2010) 0.92
From anxiety to autism: spectrum of abnormal social behaviors modeled by progressive disruption of inhibitory neuronal function in the basolateral amygdala in Wistar rats. Psychopharmacology (Berl) (2007) 0.92
Pharmacological strategies for trichotillomania. Expert Opin Pharmacother (2005) 0.92
Impact of acamprosate on behavior and brain-derived neurotrophic factor: an open-label study in youth with fragile X syndrome. Psychopharmacology (Berl) (2013) 0.92